...
首页> 外文期刊>Intestinal research. >Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
【24h】

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries

机译:预测结果以优化日本炎症性肠病的疾病管理:与西方国家的异同

获取原文
           

摘要

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
机译:包括克罗恩氏病(CD)和溃疡性结肠炎(UC)在内的炎性肠病(IBD)是胃肠道的慢性炎性疾病,在世界范围内患病率呈上升趋势。 IBD Ahead是一项国际教育计划,旨在探讨临床医生通常对IBD护理各个领域提出的问题,并将可用的公开证据和专家意见合并为优化IBD管理的共识。鉴于日本和世界其他地区患者在IBD的流行病学,临床和遗传特征,治疗和预后方面存在差异,该声明是作为IBD Ahead计划的一部分在日本专家之间进行文献综述和讨论的结果而制定的巩固IBD疾病预后因素的陈述。将证据级别分配给以下几类的摘要陈述:CD和UC中的疾病进展;手术,住院,肠衰竭和CD永久性造口;急性重度UC; UC结肠切除术;和IBD中的大肠癌和不典型增生。目的是该声明有助于优化日本IBD患者的治疗策略,并帮助确定需要早期干预的高危患者,从而为这些患者提供更好的长期预后。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号